After understanding variant-specific ACE2 competition following natural infection, we evaluated the ability of anti-SARS-CoV-2 antibodies generated by the Wuhan strain-based COVISHIELD vaccine in targeting SARS-CoV-2 variants employed in the MSD assay. This evidence concerns the gene ACE2 and infection.